NCT03797924

Intercostobrachial Nerve Block (ICBN) for Tourniquet Pain: Is it Necessary?

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: University of Florida · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

In this study the investigators would like to show that when patients undergo upper limb surgery under supraclavicular brachial plexus block, additional blocking of the Intercostobrachial Nerve Block (ICBN) does not affect the incidence or course of tourniquet pain.

Detailed description

The ICBN is a cutaneous sensory nerve that supplies the medial aspect of the upper arm. Traditionally this nerve is blocked to alleviate tourniquet pain. The etiology of tourniquet pain is complex and the study team hypothesize that blocking the ICBN has no impact on tourniquet pain. Patients will receive a supraclavicular block and be divided into two groups; ICBN with local anesthetic or ICBN with saline. All patients in this study will receive a supraclavicular block as their primary anesthetic and then be divided into two groups; those who receive ICBN and those who do not. Amount of intraoperative analgesics, conversion to deep sedation or general anesthesia, and onset of time to tourniquet pain will be the primary measures of this study.

Conditions

• Nerve Block
• Pain

Interventions

Type	Name	Description
DRUG	Receive ICBN with ropivacaine	ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
BEHAVIORAL	No ICBN block	The site of injection will be prepped with tinted chlorhexidine

Timeline

• Start date: 2019-04-25
• Primary completion: 2020-12-20
• Completion: 2021-12-13
• First posted: 2019-01-09
• Last updated: 2022-05-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study